$PAXH
PREAXIA HEALTH CARE PAYMENT SYSTEMS INC.

2024 Q4 Form 10-K Financial Statement

#000126246324000089 Filed on October 10, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q2 2024
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.120K $93.82K
YoY Change -85.79% -37.34%
% of Gross Profit
Research & Development $5.632K
YoY Change -13.73%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.610K $99.45K
YoY Change -87.65% -36.36%
Operating Profit -$99.45K
YoY Change -36.36%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$4.610K -$99.45K
YoY Change -87.65% -36.36%
Income Tax
% Of Pretax Income
Net Earnings -$4.610K -$99.45K
YoY Change -87.65% -36.36%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01
Diluted Earnings Per Share $0.00 -$0.01
COMMON SHARES
Basic Shares Outstanding 19.77M shares 19.77M shares 19.77M shares
Diluted Shares Outstanding 19.77M shares

Balance Sheet

Concept 2024 Q4 2024 Q2 2024
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.00 $10.00
YoY Change 0.0% 0.0%
Cash & Equivalents $14.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $14.00 $10.00
YoY Change 133.33% 0.0%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $14.00 $10.00
Total Long-Term Assets $0.00 $0.00
Total Assets $14.00 $10.00
YoY Change 133.33% 0.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $466.9K $466.9K
YoY Change 17.21% 17.21%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.717M $1.717M
YoY Change 1.1% 1.1%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.396M $2.396M
YoY Change 4.33% 4.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.396M $2.396M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $2.396M $2.396M
YoY Change 4.33% 4.33%
SHAREHOLDERS EQUITY
Retained Earnings -$5.128M
YoY Change 1.98%
Common Stock $19.77K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.396M -$2.396M
YoY Change
Total Liabilities & Shareholders Equity $14.00 $10.00
YoY Change 133.33% 0.0%

Cashflow Statement

Concept 2024 Q4 2024 Q2 2024
OPERATING ACTIVITIES
Net Income -$4.610K -$99.45K
YoY Change -87.65% -36.36%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.620K -$30.89K
YoY Change -36.04% -17.89%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.440K $30.88K
YoY Change -56.66% -17.35%
NET CHANGE
Cash From Operating Activities -3.620K -$30.89K
Cash From Investing Activities 0.000 $0.00
Cash From Financing Activities 2.440K $30.88K
Net Change In Cash -1.180K -$6.00
YoY Change 3833.33% -97.63%
FREE CASH FLOW
Cash From Operating Activities -$3.620K -$30.89K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024 dei Document Transition Report
DocumentTransitionReport
false
CY2024 dei Entity File Number
EntityFileNumber
000-53490
CY2024 dei Entity Address Address Line2
EntityAddressAddressLine2
1610-37thStreet S.W.
CY2024 dei Entity Central Index Key
EntityCentralIndexKey
0001350156
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024 dei Document Type
DocumentType
10-K
CY2024 dei Document Annual Report
DocumentAnnualReport
true
CY2024 dei Document Period End Date
DocumentPeriodEndDate
2024-05-31
CY2024 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--05-31
CY2024 dei Entity Registrant Name
EntityRegistrantName
PREAXIA HEALTH CARE PAYMENT SYSTEMS INC.
CY2024 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2024 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4395271
CY2024 dei Entity Address Address Line1
EntityAddressAddressLine1
PO Box 34075 Westbrook PO
CY2024 dei Entity Address City Or Town
EntityAddressCityOrTown
Calgary
CY2024 dei Entity Address State Or Province
EntityAddressStateOrProvince
AB
CY2024 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
T3C 3W2
CY2024 dei City Area Code
CityAreaCode
403
CY2024 dei Local Phone Number
LocalPhoneNumber
850-4120
CY2024 dei Security12g Title
Security12gTitle
Common Stock, $0.001 par value
CY2024 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2024 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2024 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024 dei Entity Small Business
EntitySmallBusiness
true
CY2024 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024 dei Entity Shell Company
EntityShellCompany
false
CY2024 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2024 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023Q4 dei Entity Public Float
EntityPublicFloat
494059 usd
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19767698 shares
CY2024 dei Auditor Firm
AuditorFirmId
6580
CY2024 dei Auditor Name
AuditorName
GreenGrowthCPAs
CY2024 dei Auditor Location
AuditorLocation
Los Angeles, California
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
14 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
6 usd
CY2024Q2 us-gaap Assets
Assets
14 usd
CY2023Q2 us-gaap Assets
Assets
6 usd
CY2024Q2 us-gaap Loans Payable To Bank Current
LoansPayableToBankCurrent
398 usd
CY2023Q2 us-gaap Loans Payable To Bank Current
LoansPayableToBankCurrent
0 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
166909 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
158348 usd
CY2024Q2 paxh Accounts Payable And Accrued Liabilities Related Party
AccountsPayableAndAccruedLiabilitiesRelatedParty
300000 usd
CY2023Q2 paxh Accounts Payable And Accrued Liabilities Related Party
AccountsPayableAndAccruedLiabilitiesRelatedParty
240000 usd
CY2024Q2 paxh Due To Related Party Current
DueToRelatedPartyCurrent
77187 usd
CY2023Q2 paxh Due To Related Party Current
DueToRelatedPartyCurrent
64952 usd
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
191330 usd
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
173067 usd
CY2024Q2 paxh Liability For Unissued Shares Current
LiabilityForUnissuedSharesCurrent
134792 usd
CY2023Q2 paxh Liability For Unissued Shares Current
LiabilityForUnissuedSharesCurrent
134792 usd
CY2024Q2 paxh Promissory Note Related Party
PromissoryNoteRelatedParty
466817 usd
CY2023Q2 paxh Promissory Note Related Party
PromissoryNoteRelatedParty
466817 usd
CY2024Q2 paxh Convertible Note Payable Related Party
ConvertibleNotePayableRelatedParty
1058760 usd
CY2023Q2 paxh Convertible Note Payable Related Party
ConvertibleNotePayableRelatedParty
1058760 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2396193 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2296736 usd
CY2024Q2 us-gaap Liabilities
Liabilities
2396193 usd
CY2023Q2 us-gaap Liabilities
Liabilities
2296736 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
19768 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
19768 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2655236 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2655236 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
57197 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
57197 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5128380 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5028931 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-2396179 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2296730 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6 usd
CY2024 us-gaap Revenues
Revenues
0 usd
CY2023 us-gaap Revenues
Revenues
0 usd
CY2024 paxh Consulting Fees
ConsultingFees
60000 usd
CY2023 paxh Consulting Fees
ConsultingFees
120442 usd
CY2024 us-gaap Professional Fees
ProfessionalFees
18654 usd
CY2023 us-gaap Professional Fees
ProfessionalFees
15504 usd
CY2024 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15163 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13792 usd
CY2024 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5632 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6528 usd
CY2024 us-gaap Operating Expenses
OperatingExpenses
99449 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
156266 usd
CY2024 us-gaap Operating Income Loss
OperatingIncomeLoss
-99449 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-156266 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-99449 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-156266 usd
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19767698 shares
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19767698 shares
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19767698 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19767698 shares
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-99449 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-2396179 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2296730 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-99449 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-156266 usd
CY2024 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
60000 usd
CY2023 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
120000 usd
CY2024 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
8561 usd
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1351 usd
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30888 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37617 usd
CY2024 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2024 us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
398 usd
CY2023 us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
0 usd
CY2024 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
18263 usd
CY2023 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
4992 usd
CY2024 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
13893 usd
CY2023 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
33157 usd
CY2024 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
1658 usd
CY2023 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
785 usd
CY2024 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30882 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37364 usd
CY2024 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
8 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-253 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
259 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6 usd
CY2024 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2024 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2024 us-gaap Profit Loss
ProfitLoss
-99449 usd
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30888 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-2396179 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5128380 usd
CY2024 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_841_eus-gaap--UseOfEstimates_zj6h0rw2w5Kk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_86F_zAbSz4P0iON2">Use of Estimates</span> </span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in these consolidated financial statements and accompanying notes. Although these estimates are based on management’s knowledge of current events and actions that our company may undertake in the future, actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2024 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5632 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6528 usd
CY2024 us-gaap Revenues
Revenues
0 usd
CY2023 us-gaap Revenues
Revenues
0 usd
CY2024 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
Tax years 2008 through 2024 are open for examination by taxing authorities.
CY2024Q2 paxh Operating Losses Carryforwards
OperatingLossesCarryforwards
4227000 usd
CY2024Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
919796 usd
CY2023Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
911512 usd
CY2024Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
919796 usd
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
911512 usd
CY2024Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2023Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2024 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8284 usd
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7615 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001262463-24-000089-index-headers.html Edgar Link pending
0001262463-24-000089-index.html Edgar Link pending
0001262463-24-000089.txt Edgar Link pending
0001262463-24-000089-xbrl.zip Edgar Link pending
ex31.htm Edgar Link pending
ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
imagesig.jpg Edgar Link pending
image_001.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
paxh-20240531.xsd Edgar Link pending
paxh5312024k.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
paxh-20240531_pre.xml Edgar Link unprocessable
paxh-20240531_def.xml Edgar Link unprocessable
paxh-20240531_cal.xml Edgar Link unprocessable
paxh-20240531_lab.xml Edgar Link unprocessable
paxh5312024k_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending